Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - olaratumab - sarcoma - aġenti antineoplastiċi - lartruvo hija indikata fil kombinazzjoni ma ' doxorubicin għat-trattament tal-pazjenti adulti b ' sarcoma artab avvanzati tat-tessuti li m'humiex soġġetti għal trattament kurattivi bil-kirurġija jew radjoterapija u li ma ġewx qabel trattati b ' doxorubicin (ara taqsima 5.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - portrazza flimkien ma ' gemcitabine u cisplatin chemotherapy huwa indikat għall-kura ta ' adulti pazjenti li r-riċevitur avvanzat lokalment jew metastatic epidermiku fattur tat-tkabbir (egfr) li jesprimu l-kanċer tal-pulmun taċ-ċellola mhux-żgħar squamous li ma li jaslu chemotherapy minn qabel għal din il-kondizzjoni.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - disturbi fl-emigranja - analġeżiċi - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - kolite, ulċerattiva - immunosoppressanti - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulina lispro - diabetes mellitus - drogi użati fid-dijabete - għat-trattament ta 'adulti u tfal b'dijabete mellitus li jeħtieġu l-insulina għall-manteniment ta' omeostasi normali tal-glukożju. liprolog huwa indikat ukoll għall-istabbilizzazzjoni inizjali tad-dijabete mellitus.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplażmi tas-sider - aġenti antineoplastiċi - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly and company limited  - meloxicam - sistema musculo-skeletali - klieb - tnaqqis ta 'infjammazzjoni u uġigħ kemm fid-disturbi muskuloskeletali akuti kif ukoll kroniċi.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - disturbi fl-emigranja - analgesics, galcanezumab - emgality huwa indikat għall-profilassi ta ' l-emigranja fl-adulti li jkollhom mill-anqas 4-emigranja jiem kull xahar.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - pemetrexed - mesothelioma; carcinoma, non-small-cell lung - aġenti antineoplastiċi - plewrali malinna mesotheliomaalimta flimkien ma ' cisplatin huwa indikat għat-trattament tal-kimoterapija il-pazjenti naïve b'mesoteljoma plewrali malinna u li ma jistax jitneħħa. mhux żgħar tal-pulmun taċ-ċelluli canceralimta flimkien ma 'cisplatin huwa indikat għall-kura tal-ewwel linja ta' pazjenti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelloli tal-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi. alimta huwa indikat bħala monoterapija għall-kura ta 'manteniment ta lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelloli tal-kanċer l-oħra mill-aktar istoloġija ta' ċelluli skwamużi fir-pazjenti li l-marda tagħhom ma jkunx hemm progress immedjatament wara ibbażat fuq il-platinu ' kimoterapija. alimta huwa indikat bħala monoterapija għall-tieni linja ta 'trattament ta' pazjenti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelloli tal-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi.

Euroopan unioni - malta - EMA (European Medicines Agency)

eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. f'nisa wara l-menopawża, intwera tnaqqis sinifikanti fl-inċidenza ta 'ksur vertebrali u mhux vertebrali iżda mhux fratturi tal-ġenbejn. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.